ArticleFrontiers in cardiovascular medicine2026
Case Report: Heparin-induced thrombocytopenia leads to acute myocardial infarction post-PCI in multi-vessel coronary artery disease.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-induced thrombocytopenia (HIT) is a rare but severe complication of heparin therapy, characterized by a significant reduction in platelet count and a paradoxical prothrombotic state, which increases the risks of both arterial and venous thrombosis. This case report describes a 58-year-old male patient with multi-vessel coronary artery disease who developed acute ST-segment elevation myocardial infarction (STEMI) following successful percutaneous coronary intervention (PCI). Despite initial successful revascularization, the patient experienced recurrent chest pain, and HIT was clinically suspected based on a significant drop in platelet count and the 4Ts scoring system, though confirmatory anti-PF4/heparin antibody testing was unavailable at our institution. Treatment with corticosteroids was initiated; however, following transfer to another hospital, the patient received platelet transfusion-a contraindicated intervention in HIT-and subsequently succumbed to a fatal arrhythmic event. This case highlights the diagnostic and therapeutic challenges of suspected HIT in PCI patients, where it may mimic other post-procedural complications such as stent thrombosis. It underscores the critical need for vigilant monitoring of platelet counts, timely access to confirmatory diagnostic testing, immediate initiation of guideline-recommended non-heparin anticoagulants, and seamless communication during inter-hospital transfers to prevent potentially harmful interventions and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.